# 1 SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality

2

3	Jesse Fajnzylber <sup>1*</sup> , James Regan <sup>1*</sup> , Kendyll Coxen <sup>1*</sup> , Heather Corry <sup>1*</sup> , Colline Wong <sup>1</sup> , Alexandra			
4	Rosenthal <sup>1</sup> , Daniel Worrall <sup>2</sup> , Francoise Giguel <sup>3</sup> , Alicja Piechocka-Trocha <sup>2</sup> , Caroline Atyeo <sup>2</sup> ,			
5	Stephanie Fischinger <sup>2</sup> , Andrew Chan <sup>3</sup> , Keith T. Flaherty <sup>3</sup> , Kathryn Hall <sup>3</sup> , Michael Dougan <sup>3</sup> ,			
6	Edward T. Ryan <sup>3</sup> , Elizabeth Gillespie <sup>1</sup> , Rida Chishti <sup>1</sup> , Yijia Li <sup>1</sup> , Nikolaus Jilg <sup>1,3</sup> , Dusan			
7	Hanidziar <sup>3</sup> , Rebecca M. Baron <sup>1</sup> , Lindsey Baden <sup>1</sup> , Athe M. Tsibris <sup>1</sup> , Katrina A. Armstrong <sup>3</sup> ,			
8	Daniel R. Kuritzkes <sup>1</sup> , Galit Alter <sup>2,3</sup> , Bruce D. Walker <sup>2,3,4</sup> , Xu Yu <sup>2,3</sup> , and Jonathan Z. Li <sup>1</sup> , for the			
9	Massachusetts Consortium for Pathogen Readiness			
10				
11	1. Brigham and Women's Hospital, Harvard Medical School, Boston, MA			
12	2. Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA			
13	3. Massachusetts General Hospital, Harvard Medical School, Boston, MA			
14	4. Howard Hughes Medical Institute, Chevy Chase, MD			
15				
16	*Contributed equally to this article			
17	A list of the Massachusetts Consortium for Pathogen Readiness contributors is provided in the			
18	Supplementary Appendix			
19				
20				
21	Corresponding Author:			
22	Jonathan Li, MD			
23	Brigham and Women's Hospital			

24	65 Landsdowne Street, Rm 421
25	Cambridge, MA 02139
26	jli@bwh.harvard.edu
27	
28	Short title: Clinical impact of SARS-CoV-2 viremia
29	
30	Keywords: COVID-19, SARS-CoV-2, mortality, hospitalized, respiratory tract, plasma viral
31	load
32	
33	Financial support:
34	This study was supported in part by the Massachusetts Consortium for Pathogen Readiness
35	through grants from the Evergrande Fund, Mark and Lisa Schwartz (to Drs. Li and Yu), Nancy
36	Zimmerman (to Dr. Alter), NIH grants U01AI106701 (to Dr. Li), by the Harvard University
37	Center for AIDS Research (NIAID 5P30AI060354), 3R37AI080289 (to Dr. Alter), CDC grant
38	U01CK000490 (to Dr. Ryan), and the SAMANA Kay MGH Scholar program (to Dr. Alter).
39	
40	Disclosures:
41	Dr. Li has consulted for Abbvie and Jan Biotech. Dr. Alter is the founder of Seromyx Inc.
42	
43	
44	ABSTRACT
45	The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely
46	undefined in coronavirus disease 2019 (COVID-19). We quantified SARS-CoV-2 viral load

47	from participants with a diverse range of COVID-19 severity, including those requiring
48	hospitalization, outpatients with mild disease, and individuals with resolved infection. SARS-
49	CoV-2 plasma RNA was detected in 27% of hospitalized participants and 13% of outpatients
50	diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, higher
51	prevalence of detectable SARS-CoV-2 plasma viral load was associated with worse respiratory
52	disease severity, lower absolute lymphocyte counts, and increased markers of inflammation,
53	including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma viremia, were
54	associated with increased risk of mortality. SARS-CoV-2 viral load may aid in the risk
55	stratification of patients with COVID-19 and its role in disease pathogenesis should be further
56	explored.

57

## 58 INTRODUCTION

In coronavirus disease 2019 (COVID-19), the relationship between levels of viral replication and 59 disease severity remains unclear. In prior analyses of the SARS-CoV-1 outbreak, viral load 60 within the nasopharynx was associated with worsened disease severity and increased mortality<sup>1,2</sup>. 61 However, it is also clear that there are significant differences between SARS-CoV-1 and 2, 62 including differences in the temporal nature of viral shedding<sup>3,4</sup>, transmissibility<sup>5</sup>, epidemiology<sup>6</sup>, 63 and clinical manifestations<sup>7,8</sup>. Additional studies are needed to determine whether the degree of 64 SARS-CoV-2 viral load within the respiratory tract or other compartments may predict disease 65 outcomes. 66

The need for additional SARS-CoV-2 viral studies is not only limited to respiratory 67 specimens but extends to the blood. Respiratory failure is the primary cause of death in patients 68 with COVID-19, but complications arising from a hyperactive immune response and vascular 69 damage are also prominently featured both in the pulmonary and extrapulmonary systems<sup>9-13</sup>. In 70 71 addition, there is a suggestion that detectable plasma viremia using a qualitative qPCR assay may correlate with disease severity<sup>14</sup>, although studies to date have been hampered by the lack of viral 72 load quantification. Together, these findings suggest the importance of systemic SARS-CoV-2 73 74 viral circulation, but little is known about the prevalence and magnitude of plasma viremia in 75 predicting COVID-19 outcomes. In this study, we quantified SARS-CoV-2 viral load from the 76 respiratory tract, plasma and urine of participants with a diverse range of COVID-19 severity, 77 including individuals requiring hospitalization, symptomatic non-hospitalized participants, and those recovered from COVID-19 disease. 78

### 79 **RESULTS**

#### 80 Participant characteristics and SARS-CoV-2 viral loads

We enrolled 88 hospitalized participants with COVID-19, 94 symptomatic individuals who were 81 evaluated in a respiratory infection clinic, of whom 16 were diagnosed with COVID-19 by 82 standard clinical testing of nasopharyngeal swabs, and 53 participants diagnosed with COVID-19 83 84 who had symptomatically recovered. Table 1 shows baseline demographic information, disease severity and hospital outcomes. Hospitalized participants were significantly older than both 85 symptomatic outpatients and individuals recovered from COVID-19 (Kruskal-Wallis P<0.001). 86 Participants recruited in the outpatient setting had the shortest time between the start of 87 symptoms and the time of sample collection (median 5 days) compared to hospitalized 88 individuals (median 13 days) and recovered participants (median 27 days). 89 We report SARS-CoV-2 viral load analysis both as a continuous variable and analyzed as 90 a categorical variable (detectable versus undetectable) given that only qualitative commercial 91 92 qPCR testing is available for clinical care. Amongst hospitalized individuals, the majority still 93 had detectable SARS-CoV-2 RNA at the time of initial sample collection, including 50% with 94 detectable SARS-CoV-2 RNA by nasopharyngeal swab, 67% by oropharyngeal swab, and 85% 95 by sputum testing. We also performed SARS-CoV-2 viral load testing from specimens outside of the respiratory tract and found that 27% of participants had detectable SARS-CoV-2 plasma 96 97 viremia and 10% had detectable viral RNA in the urine (Fig 1). In those with detectable plasma 98 viremia, the median viral load was 2.4  $\log_{10}$  RNA copies/mL (range 1.8 – 3.8  $\log_{10}$  RNA 99 copies/mL), which was significantly lower than that detected in sputum (median 4.4  $\log_{10}$  RNA 100 copies/mL, range  $1.8 - 9.0 \log_{10}$  RNA copies/mL, Wilcoxon signed-rank P < 0.001).

Levels of SARS-CoV-2 viral load were significantly correlated between each of the different respiratory specimen types (nasopharyngeal vs oropharyngeal Spearman r = 0.34, P =0.03; nasopharyngeal vs sputum r = 0.39, P = 0.03, oropharyngeal vs sputum r = 0.56, P = 0.001, Supplemental Fig 1). Plasma viral load was modestly associated with both nasopharyngeal (r =0.32, P = 0.02) and sputum viral loads (r = 0.36, P = 0.049), but not significantly associated with oropharyngeal viral loads. There was no significant association between urine viral load and viral loads from any other sample types.

108

### 109 SARS-CoV-2 viral load is associated with disease severity and laboratory abnormalities

Detectable plasma viremia was generally associated with increased disease severity amongst 110 hospitalized participants as 44% of those on a ventilator had detectable viremia compared to 19% 111 112 of those receiving supplemental oxygen by nasal cannula and 0% of individuals not requiring supplemental oxygen ( $X^2 P = 0.006$ , Fig 1b). Two of the 16 (13%) COVID-19 diagnosed 113 114 outpatients were found to also have detectable SARS-CoV-2 plasma viremia, compared to none of the 74 outpatients with negative clinical nasopharyngeal testing for SARS-CoV-2 RNA and 115 none of the 53 recovered individuals who had previously been diagnosed with COVID-19. None 116 117 of the 18 plasma samples from intensive care unit participants collected in the pre-COVID era were found to have detectable plasma SARS-CoV-2 RNA. 118

In hospitalized participants, higher plasma viral loads were significantly associated with
 several markers of inflammation and disease severity, including lower absolute lymphocyte

121 counts (Spearman r = -0.31, P = 0.008), and higher levels of both CRP (r = 0.40, P < 0.001) and

122 IL-6 (r = 0.50, P < 0.001). Significant associations were also detected between nasopharyngeal

and sputum viral loads and these three markers (Fig 2a). When analyzed as a categorical

124	variable, individuals with detectable plasma, nasopharyngeal or sputum viral loads had
125	significantly lower absolute lymphocyte counts, and higher CRP and IL-6 levels compared to
126	those without detectable plasma viremia (Fig 2b-d). Plasma, nasopharyngeal and/or
127	oropharyngeal viral loads were also significantly associated with increased levels of the
128	inflammatory cytokines IL-8, IP-10, MCP1, IFN-γ, and IL-1RA (Fig 2a).

129

### 130 SARS-CoV-2 viral loads and mortality risk

131 Compared to individuals who were discharged from the hospital, those who eventually died had significantly higher levels of plasma viremia at the time of initial sampling (median plasma viral 132 load 1.0 vs 2.0  $\log_{10}$  RNA copies/mL, P = 0.009, Fig 3a), which occurred a median 11 days 133 before death. For hospitalized individuals with initial detectable viremia, 32% died vs 8% of 134 those without initial viremia (OR 5.5, P = 0.02, Fig 3e). We performed a sensitivity analysis to 135 assess whether plasma viremia may also predict mortality in those with the most severe disease. 136 137 For participants who were on ventilatory support at the time of initial sample collection, 43% of those with detectable plasma viremia died compared to 17% of those without detectable plasma 138 viremia, although this comparison did not reach statistical significance (OR 3.8, P = 0.11). We 139 140 also performed an analysis in older participants as the majority of participants who died were at least 70 years old. In those  $\geq$ 70 years old with initial plasma viremia, 6 of 7 died (86%) vs 2 of 9 141 142 (22%) without initial viremia (OR 21, P = 0.02). Levels of SARS-CoV-2 viral load in respiratory 143 secretions were also higher in those who eventually died (Fig 3b-d), although the presence or 144 absence of detectable respiratory secretion viral RNA were not significantly associated with increased risk of death (Fig 3f-h). Logistic regression analysis was also performed with viral 145

- 146 loads as a continuous variable and plasma, oropharyngeal and sputum viral loads were all
- 147 associated with increased risk of death (Supplementary Table 1).
- 148 A subset of hospitalized participants had longitudinal viral load measurements. Levels of
- 149 plasma and respiratory viral loads declined from the first and second sampling time points in
- almost all participants, regardless of eventual participant outcome (Fig 4).

### 151 DISCUSSION

We report a comprehensive analysis of SARS-CoV-2 respiratory tract, plasma, and urine viral 152 loads of 235 participants who were either hospitalized with COVID-19, evaluated as 153 symptomatic outpatients, or had recovered from COVID-19 disease. The results show a 154 relatively high prevalence of SARS-CoV-2 plasma viremia in hospitalized individuals with 155 156 severe disease, but plasma viremia was also detected in symptomatic non-hospitalized participants. Levels of SARS-CoV-2 viremia was also associated with markers of inflammation 157 and disease severity, including low lymphocyte counts, and elevated CRP and IL-6 levels. To 158 159 our knowledge, this is also the first report that SARS-CoV-2 viral loads, especially detectable plasma viremia, predicted the risk of death. 160 In contrast to prior reports suggesting that the SARS-CoV-2 viral infection is largely 161 confined to the respiratory and gastrointestinal tracts<sup>15,16</sup>, we were able to detect plasma viremia 162 in a substantial proportion of both hospitalized and non-hospitalized participants. The prevalence 163 of SARS-CoV-2 plasma viremia was lower than that found in respiratory secretions, but 164

165 detectable plasma viremia had a clear relationship with concurrent clinical disease severity,

166 lower absolute lymphocyte count, higher levels of inflammation and increased risk of death.

167 Across the spectrum of viral infections, the extent of viral load has been a predictor of disease

severity and progression, including for HIV<sup>17,18</sup>, Ebola<sup>19</sup>, influenza and other non-COVID-19

169 respiratory viral infections $^{20-22}$ . The detection of plasma viral load has been described for both

170 SARS-CoV- $1^{23,24}$  and SARS-CoV- $2^{14}$ , but its role in pathogenesis and ability to predict clinical

171 outcomes remains unresolved. To our knowledge, this is the first report demonstrating that

172 SARS-CoV-2 is frequently detectable in plasma and that detectable viral load, both in plasma

and the respiratory tract, are associated with increased disease severity and mortality. Therefore,

174	the detection and quantification of viral RNA levels may aid in the risk stratification of patients
175	hospitalized with COVID-19. The association between SARS-CoV-2 viral load with levels of
176	CRP and IL-6 results also suggest that active viral infection could contribute to the
177	hyperinflammatory state that is a hallmark of severe COVID-19 <sup>25</sup> . However, the causes of
178	inflammation in COVID-19 could be multifactorial, especially as a subset of participants had
179	elevated inflammatory markers without detectable plasma viremia. Additional studies are needed
180	to determine whether antiviral treatment may effectively interrupt this pathway and whether
181	levels of SARS-CoV-2 viral load could stratify patients into individuals who are more likely to
182	benefit from an antiviral agent versus those with isolated immune dysregulation who may benefit
183	more from an anti-inflammatory or immune-modifying agent <sup>13</sup> .
184	The source for the plasma viremia is still not fully defined and could reflect spillage from
185	the pulmonary tissue into the vasculature, but there is evidence that SARS-CoV-2 can also
186	directly infect endothelial cells. Angiotensin-converting enzyme 2 (ACE2) is the primary
187	receptor for SARS-CoV-2 and can be found on both arterial and venous endothelial cells <sup>26</sup> and
188	other perivascular cells <sup>27</sup> . Tissue studies have also revealed evidence of endothelitis with
189	perivascular inflammation <sup>12</sup> and the extrapulmonary spread of SARS-CoV-2 to other organs <sup>28</sup> .
190	While additional infectivity studies are needed to confirm that plasma viremia represents
191	infectious virions, these previously published support the concept that COVID-19 should be
192	considered more than an isolated respiratory tract infection and that endothelial infection and
193	systemic circulation of infectious SARS-CoV-2 virions may be contributing to the increasing
194	reports of extrapulmonary and micro- and macrovascular complications of COVID-19 that are
195	often disproportionate to the degree of disease severity <sup>9-12,29-32</sup> .

196	There is an intense search for biomarkers of COVID-19 disease progression that could
197	accelerate early-phase clinical studies of antiviral agents against SARS-CoV-2. There has been
198	an expectation that respiratory tract viral shedding could serve as such a surrogate biomarker, but
199	it is unclear if such assumptions are accurate. An example is the reported clinical benefit of
200	remdesivir <sup>33</sup> despite the lack of evidence that remdesivir significantly reduces respiratory tract
201	viral loads <sup>34</sup> . We found only modest correlations between respiratory tract viral loads and those
202	of the plasma. This highlights the need for additional studies to assess whether these anatomic
203	compartments may serve as distinct sites of viral replication and whether antiviral medications
204	might have differential effects on viral respiratory tract shedding versus plasma viremia.
205	Our study has a few notable limitations. First, sputum samples were obtained for only a
206	subset of participants as many participants were unable to generate a sample. While sputum
207	samples had the highest frequency of SARS-CoV-2 detection, this finding demonstrates a
208	potential limitation in their use as a reliable diagnostic modality. Our longitudinal analysis of
209	viral load changes was limited to a subset of participants due to limits on the frequency of blood
210	draws for hospitalized individuals and early discharges in those with relatively mild disease.
211	Additional studies of plasma viral load dynamics early in the course of disease are needed.
212	In summary, we report that SARS-CoV-2 plasma viremia is commonly detected in
213	hospitalized individuals but can also be detected in symptomatic non-hospitalized outpatients
214	diagnosed with COVID-19. SARS-CoV-2 viral loads, especially within plasma, are associated
215	with systemic inflammation, disease progression, and increased risk of death. The role of SARS-
216	CoV-2 as a mediator of vascular and extrapulmonary COVID-19 disease manifestations should
217	be further explored.

218

219

We would like to thank the participants of this trial and the dedicated clinical staff who cared for

them. We appreciate the support of the Ragon Institute of MGH, MIT and Harvard, the

# 220 Acknowledgements

221

222

223 Massachusetts General Hospital Translational and Clinical Research Center, the Brigham and Women's Hospital Center for Clinical Investigation and the Partners Biobank. 224 225 Appendix. Massachusetts Consortium for Pathogen Readiness (MassCPR) contributors: 226 Betelihem A. (Betty) Abayneh<sup>3</sup>, Patrick Allen<sup>3</sup>, Diane Antille<sup>3</sup>, Alejandro Balazs<sup>2,3</sup>, Julia Bals<sup>2,3</sup>, 227 Max Barbash<sup>2,3</sup>, Yannic Bartsch<sup>2,3</sup>, Julie Boucau<sup>2,3</sup>, Siobhan Boyce<sup>3</sup>, Joan Braley<sup>3</sup>, Karen 228 Branch<sup>3</sup>, Katherine Broderick<sup>3</sup>, Julia Carney<sup>3</sup>, Josh Chevalier<sup>2,3</sup>, Manish C Choudhary<sup>1</sup>, Navin 229 Chowdhury<sup>2,3</sup>, Trevor Cordwell<sup>1</sup>, George Daley<sup>4</sup>, Susan Davidson<sup>3</sup>, Michael Desjardins<sup>1</sup>, Lauren 230 Donahue<sup>1</sup>, David Drew<sup>3</sup>, Kevin Einkauf<sup>2,3</sup>, Sampson Elizabeth<sup>1</sup>, Ashley Elliman<sup>3</sup>, Behzad 231 Etemad<sup>1</sup>, Jon Fallon<sup>2,3</sup>, Liz Fedirko<sup>2,3</sup>, Kelsey Finn<sup>2,3</sup>, Jeanne Flannery<sup>3</sup>, Pamela Forde<sup>3</sup>, Pilar 232 Garcia-Broncano<sup>2,3</sup>, Elise Gettings<sup>3</sup>, David Golan<sup>4</sup>, Kirsten Goodman<sup>1</sup>, Amanda Griffin<sup>3</sup>, Sheila 233 Grimmel<sup>3</sup>, Kathleen Grinke<sup>3</sup>, Ciputra Adijaya Hartana<sup>2,3</sup>, Meg Healy<sup>3</sup>, Howard Heller<sup>3,4</sup>, 234 Deborah Henault<sup>3</sup>, Grace Holland<sup>3</sup>, Chenyang Jiang<sup>2,3</sup>, Hannah Jordan<sup>1</sup>, Paulina Kaplonek<sup>2,3</sup>, 235 Elizabeth W. Karlson<sup>1</sup>, Marshall Karpell<sup>2,3</sup>, Chantal Kayitesi<sup>3</sup>, Evan C. Lam<sup>2,3</sup>, Vlasta LaValle<sup>3</sup>, 236 Kristina Lefteri<sup>2,3</sup>, Xiaodong Lian<sup>2,3</sup>, Mathias Lichterfeld<sup>1,3</sup>, Daniel Lingwood<sup>2,3</sup>, Hang Liu<sup>2,3</sup>, 237 Jinqing Liu<sup>2,3</sup>, Kell Lopez<sup>1</sup>, Yuting Lu<sup>3</sup>, Sarah Luthern<sup>3</sup>, Ngoc L. Ly<sup>2,3</sup>, Maureen MacGowan<sup>1</sup>, 238 Karen Magispoc<sup>1</sup>, Jordan Marchewka<sup>3</sup>, Brittani Martino<sup>3</sup>, Roseann McNamara<sup>3</sup>, Ashlin 239 Michell<sup>2,3</sup>, Ilan Millstrom<sup>2,3</sup>, Noah Miranda<sup>2,3</sup>, Christian Nambu<sup>3</sup>, Susan Nelson<sup>3</sup>, Marjorie 240 Noone<sup>3</sup>, Lewis Novack<sup>1</sup>, Claire O'Callaghan<sup>2,3</sup>, Christine Ommerborn<sup>3</sup>, Matthew Osborn<sup>2,3</sup>, Lois 241 Chris Pacheco<sup>3</sup>, Nicole Phan<sup>3</sup>, Shiv Pillai<sup>2,3</sup>, Falisha A. Porto<sup>3</sup>, Yelizaveta Rassadkina<sup>2,3</sup>, 242

243	Alexandra Reissis <sup>2,3</sup> , Francis Ruzicka <sup>2,3</sup> , Kyra Seiger <sup>2,3</sup> , Kathleen Selleck <sup>3</sup> , Libera Sessa <sup>2,3</sup> ,		
244	Arlene Sharpe <sup>4</sup> , Christianne Sharr <sup>2,3</sup> , Sally Shin <sup>2,3</sup> , Nishant Singh <sup>2,3</sup> , Sue Slaughenhaupt <sup>3</sup> ,		
245	Kimberly Smith Sheppard <sup>3</sup> , Weiwei Sun <sup>2,3</sup> , Xiaoming Sun <sup>2,3</sup> , Elizabeth (Lizzie) Suschana <sup>3</sup> ,		
246	Opeyemi Talabi <sup>1</sup> , Hannah Ticheli <sup>2,3</sup> , Scott T. Weiss <sup>1</sup> , Vivine Wilson <sup>3</sup> , Alex Zhu <sup>2,3</sup>		
247			
248	1. Brigham and Women's Hospital, Harvard Medical School, Boston, MA		
249	2. Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA		
250	3. Massachusetts General Hospital, Harvard Medical School, Boston, MA		
251	4. Harvard Medical School, Boston, MA		
252			
253			
254			

### 255 METHODS

### 256 Participant enrollment and sample collection

We enrolled hospitalized and non-hospitalized participants with COVID-19 in a longitudinal 257 sample collection study at two academic medical centers. Blood was collected from consented 258 hospitalized participants diagnosed with COVID-19, non-hospitalized symptomatic individuals 259 260 seeking care at a respiratory infection clinic, and participants who had recovered from known 261 COVID-19 disease. Nasopharyngeal swabs, oropharyngeal swabs, sputum, and urine were also collected from hospitalized participants. Nasopharyngeal swabs and oropharyngeal swabs were 262 263 collected in 3 mL of phosphate buffered saline (PBS). A subset of hospitalized participants had longitudinal samples collected. Plasma obtained from a cohort of individuals in the intensive 264 care unit from the pre-COVID-19 era were used as a comparator group<sup>35</sup>. Each participant's 265 266 electronic medical record was reviewed to determine the oxygenation status (room air, on oxygen by nasal cannula, or requiring ventilator support), demographics, comorbidities and the 267 outcome of the hospitalization (discharge or death). This study was approved by the Partners 268 Institutional Review Board. 269

270

#### 271 Markers of inflammation and disease severity

Levels of C-reactive protein (CRP) and absolute lymphocyte count were recorded from the
electronic medical record. Thirty-five additional markers of inflammation were evaluated in
plasma by the Luminex xMAP assay (ThermoFisher): EGF, Eotaxin, FGF-basic, G-CSF, GMCSF, HGF, IFN-α, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2R, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-9, IL-10, IL-12 (p40/p70) IL-13, IL-15, IL-17A, IL-17F, IL-22, IP-10, MCP-1, MIG, MIP-1α,
MIP-1β, RANTES, TNF-α, and VEGF.

### 278 SARS-CoV-2 Viral Load Quantification

Levels of SARS-CoV-2 viral load were quantified using the US CDC 2019-nCoV\_N1 primers 279 and probe set<sup>36</sup>. Virions were pelleted from respiratory secretions, swab fluids, plasma, or urine 280 by centrifugation at approximately 21,000 x g for 2 hours at 4°C. The supernatant was removed 281 and 750 µL of TRIzol-LS<sup>TM</sup> Reagent (ThermoFisher) was added to the pellets and then incubated 282 283 on ice. Following incubation, 200 µL of chloroform (MilliporeSigma) was added and vortexed. The mixtures were separated by centrifugation at 21,000 x g for 15 minutes at 4°C, and 284 285 subsequently the aqueous layer was removed and treated with an equal volume of isopropanol 286 (Sigma). GlycoBlue<sup>TM</sup> Coprecipitant (ThermoFisher) and 100 µL 3M Sodium Acetate (Life Technologies) were added to each sample and incubated on dry ice until frozen. RNA was 287 pelleted by centrifugation at 21,000 x g for 45 minutes at 4°C. The supernatant was discarded 288 289 and the RNA was washed with cold 70% ethanol. The RNA was resuspended in DEPC-treated 290 water (ThermoFisher). Each reaction contained extracted RNA, 1X TagPath<sup>™</sup> 1-Step RT-qPCR Master Mix, 291 CG (ThermoFisher), the CDC N1 forward and reverse primers, and probe<sup>36</sup>. Viral copy numbers 292 were quantified using N1 qPCR standards in 16-fold dilutions to generate a standard curve. The 293 294 assay was run in triplicate for each sample and two non-template control (NTC) wells were

included as negative controls. Quantification of the Importin-8 (IPO8) housekeeping gene RNA
level was performed to determine the quality of respiratory sample collection. An internal virion
control (RCAS) was spiked into each sample and quantified to determine the efficiency of RNA
extraction and qPCR amplification<sup>37</sup>.

299

#### **300** Statistical analyses

Levels of SARS-CoV-2 viral load at the time of initial hospital collection were compared by site 301 of sampling, disease severity and hospital outcome. SARS-CoV-2 viral load analysis was 302 303 performed both as continuous variables with non-parametric rank-based testing and as a categorical variable (detectable vs undetectable) with Fisher's exact and  $X^2$  tests given the 304 qualitative nature of current commercial qPCR tests. SARS-CoV-2 viral loads below 40 RNA 305 306 copies/mL were categorized as undetectable and set at  $1.0 \log_{10}$  RNA copies/mL. For the subset of participants with repeated sampling, the sign test was used to assess viral load change between 307 the first and second time point. Correlation analysis was performed using Spearman rank-based 308 309 testing. In the correlation analysis between the soluble inflammatory markers and viral load, a Pvalue <0.01 between a marker and any of the viral load measurements was the threshold to 310 include that marker in the reported results. Logistic regression and other statistical analyses were 311 312 performed using GraphPad Prism 8 and SAS software, version 9.4. Only univariate analysis was performed due to the available sample size, but we did perform sensitivity analysis for plasma 313 314 viral load effects based on disease severity and age.

315

#### 316 **References**

- 317 1 Cheng, V. C. et al. Viral replication in the nasopharynx is associated with diarrhea in patients
- 318 with severe acute respiratory syndrome. *Clin Infect Dis* **38**, 467-475, doi:10.1086/382681 (2004).
- Hung, I. F. et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis 10,
- 320 1550-1557, doi:10.3201/eid1009.040058 (2004).
- 321 3 To, K. K. *et al.* Temporal profiles of viral load in posterior oropharyngeal saliva samples and
- 322 serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
- 323 *Lancet Infect Dis*, doi:10.1016/S1473-3099(20)30196-1 (2020).
- 4 Xu, K. *et al.* Factors associated with prolonged viral RNA shedding in patients with COVID-19. *Clin*
- 325 *Infect Dis*, doi:10.1093/cid/ciaa351 (2020).
- He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med*,
  doi:10.1038/s41591-020-0869-5 (2020).
- Wu, J. T. *et al.* Estimating clinical severity of COVID-19 from the transmission dynamics in
- 329 Wuhan, China. *Nat Med* **26**, 506-510, doi:10.1038/s41591-020-0822-7 (2020).
- 330 7 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*,
- 331 doi:10.1056/NEJMoa2002032 (2020).
- Li, R. *et al.* Substantial undocumented infection facilitates the rapid dissemination of novel
   coronavirus (SARS-CoV2). *Science*, doi:10.1126/science.abb3221 (2020).
- Oxley, T. J. *et al.* Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. *N Engl J Med*, doi:10.1056/NEJMc2009787 (2020).
- 336 10 Menter, T. *et al.* Post-mortem examination of COVID19 patients reveals diffuse alveolar damage
- 337 with severe capillary congestion and variegated findings of lungs and other organs suggesting
- 338 vascular dysfunction. *Histopathology*, doi:10.1111/his.14134 (2020).

- 339 11 Ackermann, M. et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in
- 340 Covid-19. *N Engl J Med*, doi:10.1056/NEJMoa2015432 (2020).
- 341 12 Varga, Z. *et al.* Endothelial cell infection and endotheliitis in COVID-19. *Lancet*,
- 342 doi:10.1016/S0140-6736(20)30937-5 (2020).
- 343 13 Giamarellos-Bourboulis, E. J. *et al.* Complex Immune Dysregulation in COVID-19 Patients with
- 344 Severe Respiratory Failure. *Cell Host Microbe*, doi:10.1016/j.chom.2020.04.009 (2020).
- 345 14 Chen, X. et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with
- 346 drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. *Clin Infect Dis*,
- 347 doi:10.1093/cid/ciaa449 (2020).
- 348 15 Wang, W. et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA,
- doi:10.1001/jama.2020.3786 (2020).
- 350 16 Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature,
- doi:10.1038/s41586-020-2196-x (2020).
- Mellors, J. W. *et al.* Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.
- 353 *Science* **272**, 1167-1170 (1996).
- 354 18 Saag, M. S. *et al.* HIV viral load markers in clinical practice. *Nat Med* **2**, 625-629,
- doi:10.1038/nm0696-625 (1996).
- Towner, J. S. *et al.* Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an
- 357 outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 78, 4330-
- 358 4341, doi:10.1128/jvi.78.8.4330-4341.2004 (2004).
- 20 Vos, L. M. *et al.* Lower respiratory tract infection in the community: associations between viral
- aetiology and illness course. *Clin Microbiol Infect*, doi:10.1016/j.cmi.2020.03.023 (2020).

- Li, C. C. et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and
- 362 prolonged viral shedding in children. *Emerg Infect Dis* **16**, 1265-1272,
- 363 doi:10.3201/eid1608.091918 (2010).
- Lee, N. *et al.* Viral loads and duration of viral shedding in adult patients hospitalized with
- 365 influenza. J Infect Dis **200**, 492-500, doi:10.1086/600383 (2009).
- 366 23 Grant, P. R. et al. Detection of SARS coronavirus in plasma by real-time RT-PCR. N Engl J Med
- **367 349**, 2468-2469, doi:10.1056/NEJM200312183492522 (2003).
- 368 24 Wang, W. K. *et al.* Detection of severe acute respiratory syndrome coronavirus RNA in plasma
- 369 during the course of infection. *J Clin Microbiol* **43**, 962-965, doi:10.1128/JCM.43.2.962-965.2005
- 370 (2005).
- 371 25 Blanco-Melo, D. et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-
- 372 19. *Cell* **181**, 1036-1045 e1039, doi:10.1016/j.cell.2020.04.026 (2020).
- 373 26 Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS
- 374 coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203, 631-637,
- doi:10.1002/path.1570 (2004).
- 27 Chen, L., Li, X., Chen, M., Feng, Y. & Xiong, C. The ACE2 expression in human heart indicates new
- potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovasc Res*
- 378 **116**, 1097-1100, doi:10.1093/cvr/cvaa078 (2020).
- 28 Puelles, V. G. et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med,
- 380 doi:10.1056/NEJMc2011400 (2020).
- 381 29 Spiezia, L. *et al.* COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive
- 382 Care Unit for Acute Respiratory Failure. *Thromb Haemost*, doi:10.1055/s-0040-1710018 (2020).
- 383 30 Ranucci, M. *et al.* The procoagulant pattern of patients with COVID-19 acute respiratory distress
- 384 syndrome. *J Thromb Haemost*, doi:10.1111/jth.14854 (2020).

- 385 31 Bikdeli, B. *et al.* COVID-19 and Thrombotic or Thromboembolic Disease: Implications for
- 386 Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol,
- 387 doi:10.1016/j.jacc.2020.04.031 (2020).
- 388 32 Zhang, Y. *et al.* Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. *N Engl*
- 389 *J Med* **382**, e38, doi:10.1056/NEJMc2007575 (2020).
- 390 33 Beigel, J. H. et al. Remdesivir for the Treatment of Covid-19 Preliminary Report. N Engl J Med,
- doi:10.1056/NEJMoa2007764 (2020).
- 392 34 Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-
- 393 controlled, multicentre trial. *Lancet* **395**, 1569-1578, doi:10.1016/S0140-6736(20)31022-9
- 394 (2020).
- 395 35 Boudreault, F. *et al.* Zinc deficiency primes the lung for ventilator-induced injury. *JCI Insight* **2**,
- doi:10.1172/jci.insight.86507 (2017).
- 397 36 (Centers for Disease Control and Prevention (CDC), Accessed April, 2020).
- 398 37 Palmer, S. et al. New real-time reverse transcriptase-initiated PCR assay with single-copy
- sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41, 4531-
- 400 4536 (2003).

401

# Table 1. Demographics and Clinical Characteristics of Participants at Baseline

Characteristic	Hospitalized (N=88)	Symptomatic Non- Hospitalized (N=90)	Recovered (N=53)
Female sex, %	38%	62%	65%
Age, median years [Q1,Q3]	57 [43 <i>,</i> 68]	48 [31,59]	33 [29,42]
Ethnicity			
Caucasian	35%	79%	81%
Black/African American	15%	8%	6%
Hispanic/Latino	38%	3%	6%
Other	12%	10%	8%
Comorbidities			
Hypertension	53%	22%	2%
Chronic Lung Disease	18%	30%	2%
Diabetes	40%	11%	2%
BMI			
<25	20%	35%	62%
25-29.99	35%	24%	24%
≥30	45%	40%	14%
Days Between Symptom Onset and Initial Sample			
Collection, median [Q1,Q3]	13 [10,18]	5 [2,15]	27 [20, 34]
Oxygenation Status at Time of Enrollment			
Room Air	15%		
Nasal Cannula	37%		
Ventilator	48%		
Hospitalization Status			
% discharged	85%		
% mortality	13%		





Figure 1. SARS-CoV-2 viral loads at the time of initial

**sampling.** (A) Levels of SARS-CoV-2 viral loads at the time of initial sampling and across specimen types. The percent of samples with detectable viral loads are shown at the bottom. (B) (A) Percent of participants with detectable plasma SARS-CoV-2 viral load by hospitalization status and disease severity. Symptomatic nasopharyngeal swab positive (NP+) and negative (NP-) individuals were evaluated at an outpatient respiratory infection clinic. Recovered individuals included participants who had previously been diagnosed with COVID-19, but whose symptoms have since resolved.













**Figure 4**. Longitudinal viral load measurements of samples obtained from plasma (A-B), nasopharyngeal swab (C-D), oropharyngeal swab (E-F), or Sputum (G-H). Red dots and lines show viral loads in those who died. Sign test p-values showing significant changes over time are reported in an analysis of viral loads at the first and second available time points (TP).



Supplemental Figure 1. Correlation of respiratory tract and plasma viral loads. VL, viral load.



**Supplemental Figure 2**. Detection of SARS-CoV-2 viral load from nasopharyngeal swabs (A), oropharyngeal swabs (B) and sputum (C), categorized by respiratory disease severity. P-values are from X<sup>2</sup> analysis.

Specimen Type	Variable type <sup>1</sup>	Odds Ratio	P-value
Plasma	Categorical	5.5	0.02
Nasopharyngeal	Categorical	2.4	0.25
Oropharyngeal	Categorical	3.5	0.27
Sputum <sup>2</sup>	Categorical	-	-
Plasma	Continuous	2.4	0.04
Nasopharyngeal	Continuous	1.4	0.09
Oropharyngeal	Continuous	2.1	0.02
Sputum	Continuous	2.8	0.048

Supplemental Table 1. Logistic regression analysis of association of viral load	with
risk of death	

<sup>1</sup>Categorical refers to analysis of viral loads as detectable or not detectable <sup>2</sup>There were no deaths in participants with undetectable sputum viral loads